Physician profile
Shahid Aziz
NPI 1063611697
$173,417.42
in general payments reported to CMS, 2019-2025
65 companies · $13K in 2025
The $13K reported for 2025 was more than what 91% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $23K · 2021: $16K · 2022: $39K · 2023: $25K · 2024: $23K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Food and Beverage: $15K · Travel and Lodging: $3,895 · Consulting Fee: $2,550 · Education: $92.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,047.39 |
| Food and Beverage | $14,671.19 |
| Travel and Lodging | $3,894.62 |
| Consulting Fee | $2,550.00 |
| Education | $92.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $48,700.68 | 2019-2025 | Korlym |
| Novo Nordisk INC | $35,972.99 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Intuity Medical INC | $20,112.18 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Cequr Corporation | $11,460.90 | 2022-2025 | Cequr Simplicity |
| Sanofi-Aventis U.S. LLC | $10,663.25 | 2019-2025 | |
| Lilly USA, LLC | $9,097.51 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,492.76 | 2019-2025 | Jardiance, Synjardy |
| Mannkind Corporation | $5,083.85 | 2019-2025 | Afrezza |
| Zealand Pharma US, INC. | $4,517.48 | 2020-2022 | |
| Dexcom, INC. | $4,438.49 | 2019-2025 | Dexcom G6 Transmitter |
| Ascensia Diabetes Care US INC. | $4,071.88 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $2,541.04 | 2019-2024 | Farxiga |
| Amgen INC. | $1,755.93 | 2019-2025 | Evenity, Repatha, Tepezza |
| Ibsa Pharma INC. | $1,330.72 | 2019-2022 | |
| Tandem Diabetes Care, INC. | $841.76 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $685.24 | 2022-2025 | |
| Abbvie INC. | $650.23 | 2019-2025 | Synthroid, Ubrelvy |
| Insulet Corporation | $533.48 | 2019-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $398.93 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Recordati_rare_diseases_inc. | $365.16 | 2020-2025 | Isturisa, Signifor Lar |
| Beta Bionics, INC. | $360.43 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Esperion Therapeutics, INC. | $355.39 | 2020-2025 | Nexletol |
| Amarin Pharma, INC. | $329.22 | 2019-2023 | |
| Averitas Pharma INC. | $295.15 | 2023-2024 | Qutenza |
| Janssen Pharmaceuticals, INC | $283.08 | 2019-2020 | |
| Sequel Med Tech, LLC | $277.90 | 2025 | Twiist |
| Radius Health, INC. | $270.29 | 2019-2025 | Tymlos |
| Abbott Laboratories | $251.11 | 2019-2025 | Freestyle Libre 3 |
| Antares Pharma, INC. | $197.19 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Tolmar, INC. | $165.63 | 2023-2025 | Jatenzo |
| Merck Sharp & Dohme LLC | $160.74 | 2019-2022 | |
| Horizon Therapeutics Plc | $128.56 | 2020-2023 | Tepezza |
| Medtronic, INC. | $116.47 | 2021-2025 | Minimed 780g, Inceptiv, Vanta Adaptivestim |
| Amneal Pharmaceuticals LLC | $111.33 | 2024-2025 | Unithroid |
| Ipsen Biopharmaceuticals, INC | $110.30 | 2021-2023 | Somatuline Depot |
| Neurocrine Biosciences, INC. | $104.51 | 2025 | |
| Medtronic Minimed, INC. | $94.28 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $84.25 | 2019-2025 | Strensiq |
| Nevro Corp. | $81.34 | 2023 | Senza |
| Eusa Pharma (US) LLC | $71.79 | 2022 | |
| Halozyme INC | $64.62 | 2023 | |
| Kyowa Kirin, INC. | $63.21 | 2024-2025 | Crysvita |
| Shire North American Group INC | $60.32 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.71 | 2020-2022 | |
| Eisai INC. | $51.52 | 2019 | |
| Acerus Pharmaceuticals Corporation | $50.22 | 2020-2022 | |
| Madrigal Pharmaceuticals | $50.06 | 2025 | Rezdiffra |
| Currax Pharmaceuticals LLC | $50.00 | 2023 | Nexletol |
| Becton, Dickinson and Company | $46.78 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.05 | 2021 | |
| Clarus Therapeutics INC. | $41.79 | 2021 | |
| Lifescan, INC. | $33.93 | 2020-2021 | |
| Boston Scientific Corporation | $32.71 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.84 | 2021 | |
| Bigfoot Biomedical INC | $27.96 | 2022 | |
| Ascendis Pharma Endocrinology INC | $24.18 | 2025 | Yorvipath |
| Regeneron Healthcare Solutions, INC. | $23.60 | 2019 | |
| Valeritas, INC. | $21.68 | 2019 | |
| Companion Medical, INC. | $18.93 | 2019 | |
| Glaxosmithkline, LLC. | $16.97 | 2025 | Arexvy, Shingrix |
| Vistapharm, INC. | $13.57 | 2021 | |
| Myovant Sciences INC. | $12.58 | 2022 | |
| Pfizer INC. | $12.12 | 2022 | |
| Kvk-Tech, INC. | $6.35 | 2019 | |
| Grt US Holding, INC. | $6.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahid Aziz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.